Journal Articles

Flaminal®: a novel approach to wound bioburden control

Share this article

Flaminal®: a novel approach to wound bioburden control

Richard White
31 August 2006

It is now widely accepted that wound bioburden, in chronic wounds in particular, will often require control. This is best achieved by the use of appropriate topical agents, available in safe, sustained release, broadspectrum forms. The ancillary functions, if any, of a topical antimicrobial are becoming important health economic factors. Resistance and its development is also of great interest. The new Flaminal® products are novel formulations with broad-spectrum antimicrobial activity which have the capacity to control exudate and promote rapid wound healing. These will be available on the Drug Tariff from October 2006.

Free for all healthcare professionals

Sign up to the Wounds Group journals

By clicking ‘Subscribe’, you are agreeing that the Wounds Group are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our privacy policy.

Are you a healthcare professional? This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.

We use cookies responsibly to ensure that we give you the best experience on our website. If you continue without changing your browser settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies.

I am not a healthcare professional.